Immix Biopharma Files 8-K: Corporate Updates
Ticker: IMMX · Form: 8-K · Filed: Jul 26, 2024 · CIK: 1873835
Sentiment: neutral
Topics: corporate-filing, 8-K
TL;DR
Immix Biopharma filed an 8-K on 7/25/24. Corporate info updated.
AI Summary
Immix Biopharma, Inc. filed an 8-K on July 25, 2024, reporting other events and financial statements. The filing details the company's corporate structure, including its state of incorporation (Delaware) and principal executive offices in Los Angeles, California.
Why It Matters
This filing provides essential corporate information and updates for Immix Biopharma, Inc., which is relevant for investors tracking the company's regulatory compliance and operational details.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain significant new financial or operational risks.
Key Players & Entities
- Immix Biopharma, Inc. (company) — Registrant
- July 25, 2024 (date) — Date of earliest event reported
- Los Angeles, CA (location) — Principal executive offices
- Delaware (location) — State of incorporation
FAQ
What is the exact name of the registrant?
The exact name of the registrant is Immix Biopharma, Inc.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported was on July 25, 2024.
In which state is Immix Biopharma, Inc. incorporated?
Immix Biopharma, Inc. is incorporated in Delaware.
What is the address of the company's principal executive offices?
The address of the company's principal executive offices is 11400 West Olympic Blvd., Suite 200, Los Angeles, CA 90064.
What is the registrant's telephone number?
The registrant's telephone number is (310) 651-8041.
Filing Stats: 447 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-07-26 09:30:10
Key Financial Figures
- $0.0001 — registered Common Stock, par value of $0.0001 per share IMMX The Nasdaq Stock Mar
- $8 million — ly-owned subsidiary, has been awarded a $8 million grant from the California Institute for
Filing Documents
- form8-k.htm (8-K) — 35KB
- ex99-1.htm (EX-99.1) — 26KB
- 0001493152-24-029174.txt ( ) — 239KB
- immx-20240725.xsd (EX-101.SCH) — 3KB
- immx-20240725_lab.xml (EX-101.LAB) — 33KB
- immx-20240725_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 25, 2024 IMMIX BIOPHARMA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-41159 45-4869378 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) 11400 West Olympic Blvd. , Suite 200 Los Angeles , CA 90064 (Address of principal executive offices) (310) 651-8041 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) Securities registered pursuant to Section 12(b)of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value of $0.0001 per share IMMX The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Events. On July 25, 2024, Immix Biopharma, Inc. (the " Company ") filed a press release announcing that Nexcella, Inc., its wholly-owned subsidiary, has been awarded a $8 million grant from the California Institute for Regenerative Medicine. A copy of the press release is included herewith as Exhibit 99.1 and the information in the press release is incorporated by reference into this Item 8.01 in its entirety by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release, dated July 25, 2024 104 Cover Page Interactive Data File (embedded within Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Immix Biopharma, Inc. Dated: July 26, 2024 /s/ Ilya Rachman Ilya Rachman Chief Executive Officer